Baird downgraded Maravai Lifesciences (MRVI) to Neutral from Outperform with a price target of $3, down from $9, after the company announced ...
Shares of Maravai LifeSciences Holdings, Inc. ("Maravai LifeSciences") plunged over 21% in intraday trading on Tuesday, February 25, 2025, after the company disclosed it would be delaying its 2024 ...
Law Offices of Howard G. Smith announces an investigation on behalf of Maravai LifeSciences Holdings, Inc. ("Maravai" or the "Company") investors concerning the Company's possible violations of ...